A Phase 3 interventional study of V501 in Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in China. Open to female participants aged 9 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-31.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Uterine Cervical Dysplasia with a site in China — 10 open to participants now, 14 under way, 1 of them phase 3. Uterine Cervical Dysplasia · China.
Among the 55 studies in Uterine Cervical Dysplasia with a site in China, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 7 that started in 2018, is one of 7 in phase 3, and was the 27th registered.
409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
Browse Uterine Cervical Dysplasia studies →10 of the 55 studies in Uterine Cervical Dysplasia with a site in China are open now. Recruiting first, the newest first:
Fujian Maternity and Child Health Hospital · Sites in China
Ages up to 45 · Women only
First Hospital of China Medical University · Sites in China
Ages 18–65 · Women only
Shanghai Zerun Biotechnology Co.,Ltd · Sites in China
Ages 12–34 · Women only · Healthy volunteers
Tongji Hospital · Sites in China
Ages 18–50 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18 days+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 9 Years to 26 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 7 started in 2018.
This study's enrollment of 766 is above the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.
Median enrollment 330 across the 34 interventional studies, 1,200 across the 21 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 2 studies filed under Uterine Cervical Dysplasia — fewer than ten, so there is no comparison to draw.
2 of the studies in Uterine Cervical Dysplasia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07833852Shanghai Zerun Biotechnology Co.,LtdLong-Term Immune Persistence After Bivalent HPV Vaccination in Females From Study 311-HPV-1005 | 2026-12 |
| NCT06243666Xiamen UniversityLong-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Uterine Cervical Dysplasia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the immunogenicity, safety, and tolerability of Gardasil® (quadrivalent human papillomavirus [qHPV] vaccine, V501) in Chinese girls aged 9-19 years and young women aged 20-26 years. The primary hypothesis of the study states that at 1 month postdose 3, a 3-dose regimen of V501 induces non-inferior geometric mean titers (GMTs) for serum anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18 in girls aged 9-19 years compared to young women aged 20-26 years.
The study consists of a Base Stage wherein Chinese girls aged 9-19 years and young women aged 20-26 years receive a 3-dose regimen of V501 and are followed up to 1 month postdose 3 (Month 7). Participants aged 9-19 years who received 3 doses of V501 in the Base Stage will be eligible to participate in the Extension Stage and will be followed up to Month 60. No study vaccine will be administered during the Extension Stage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
Biological: V501
Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
Biological: V501
0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
Also known as: (Gardasil®) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, qHPV
Base Stage: Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA)
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).
Time frame: Month 7 (1 month postdose 3)
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
Time frame: Month 12 post-vaccination 1
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
Time frame: Month 24 post-vaccination 1
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
Time frame: Month 36 post-vaccination 1
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
Time frame: Month 48 post-vaccination 1
Extension Stage: GMTs for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA
Serum antibody titers (Geometric mean titers) for HPV virus-like particles (VLPs) Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
Time frame: Month 60 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by cLIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
Time frame: Month 12 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by cLIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
Time frame: Month 24 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by cLIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
Time frame: Month 36 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by cLIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
Time frame: Month 48 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by cLIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
Time frame: Month 60 post-vaccination 1
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 12 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).
Time frame: Month 12 post-vaccination 1
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 24 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).
Time frame: Month 24 post-vaccination 1
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 36 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).
Time frame: Month 36 post-vaccination 1
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 48 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.
Time frame: Month 48 post-vaccination 1
Extension Stage: GMTs for Serum Anti-HPV Types 6, 11, 16, and 18 at Month 60 Assessed by Immunoglobulin G Luminex Immunoassay (IgG LIA)
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.
Time frame: Month 60 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 12 Assessed by IgG LIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
Time frame: Month 12 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 24 Assessed by IgG LIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
Time frame: Month 24 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 36 Assessed by IgG LIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
Time frame: Month 36 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 48 Assessed by IgG LIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
Time frame: Month 48 post-vaccination 1
Extension Stage: Percentage of Participants With Seropositivity to HPV Types 6, 11, 16, and 18 at Month 60 Assessed by IgG LIA
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
Time frame: Month 60 post-vaccination 1
Base Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: cLIA
Seroconversion is defined as changing serostatus from seronegative at Day 1 to seropositive at 1 month post dose 3. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).
Time frame: Month 7 (1 month postdose 3)
Base Stage: Geometric Mean Titers for Serum Anti-HPV Types 6, 11, 16, and 18: IgG LIA
Antibodies to HPV Types 6, 11, 16, and 18 were measured using an IgG LIA. Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).
Time frame: Month 7 (1 month postdose 3)
Base Stage: Percentage of Participants With Seroconversion for HPV Types 6, 11, 16, and 18: IgG LIA
The percentage of participants who seroconverted to each of HPV Types 6, 11, 16, and 18 was assessed. Antibodies were measured using IgG LIA.
Time frame: Month 7 (1 month postdose 3)
Base Stage: Percentage of Participants Who Experienced a Solicited Injection-site Adverse Event (AE)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs included injection-site redness, swelling, induration, pain, and pruritus.
Time frame: Up to 15 days after any vaccination
Base Stage: Percentage of Participants Participants Who Experienced a Solicited Systemic AE
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs included hypersensitivity, headache, fatigue, vomiting, nausea, diarrhea, myalgia, pyrexia, and cough.
Time frame: Up to 15 days after any vaccination
Base Stage: Percentage of Participants Who Experienced a Serious Adverse Event (SAE)
An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
Time frame: Up to Month 7 (1 month postdose 3)
Base Stage: Percentage of Participants Who Experienced an AE
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment
Time frame: Up to 31 days after any vaccination
Base Stage: Maximum Axillary Temperature: Merck Sharp & Dohme (MSD) Criteria
In the global studies, fever is defined as an oral temperature of ≥37.8°C or 100.0°F, which is equivalent to axillary temperature of ≥37.2°C, while the definition of fever is axillary temperature of ≥37.1°C in Chinese criteria. To be compliant to Chinese criteria, axillary temperatures of ≥37.1°C was considered as a fever in this study. Body temperature readings assessed orally were converted to the axillary equivalent. The percentage of participants with a maximum axillary or converted axillary temperature was summarized by temperature range.
Time frame: Up to 5 days after any vaccination
Extension Stage: Percentage of Participants Who Experienced an SAE
The percentage of participants with an SAE will be assessed. An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
Time frame: Month 7 up to Month 60
| Milestone | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|---|---|
| Started | 383 | 383 | 0 |
| Vaccination 1 | 383 | 383 | 0 |
| Vaccination 2 | 379 | 378 | 0 |
| Vaccination 3 | 378 | 377 | 0 |
| Completed | 383 | 379 | 0 |
| Not completed | 0 | 4 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 0 |
| Milestone | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|---|---|
| Started | 0 | 0 | 365 |
| Completed | 0 | 0 | 338 |
| Not completed | 0 | 0 | 27 |
| Withdrew: Consent withdrawal by parent/guardian | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 25 |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).
| mMU/mL | Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Anti-HPV 6 | 975.2 (905.6 to 1050.2) | 686.6 (635.5 to 741.7) |
| Anti-HPV 11 | 807.4 (749.8 to 869.4) | 580.2 (537.0 to 626.8) |
| Anti-HPV 16 | 4573.7 (4244.5 to 4928.3) | 2989.2 (2766.7 to 3229.6) |
| Anti-HPV 18 | 1176.5 (1069.0 to 1294.8) | 708.6 (642.4 to 781.6) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 259.1 (237.6 to 282.4) |
| Anti-HPV 11 | 206.7 (190.5 to 224.3) |
| Anti-HPV 16 | 1149.8 (1054.6 to 1253.7) |
| Anti-HPV 18 | 284.2 (257.3 to 313.8) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 137.9 (125.5 to 151.4) |
| Anti-HPV 11 | 110.3 (101.0 to 120.6) |
| Anti-HPV 16 | 522.6 (472.1 to 578.5) |
| Anti-HPV 18 | 157.2 (142.7 to 173.3) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 110.6 (101.3 to 120.7) |
| Anti-HPV 11 | 87.0 (79.6 to 95.2) |
| Anti-HPV 16 | 400.8 (359.5 to 446.8) |
| Anti-HPV 18 | 131.9 (120.2 to 144.8) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 103.0 (94.4 to 112.4) |
| Anti-HPV 11 | 81.8 (74.8 to 89.3) |
| Anti-HPV 16 | 347.5 (310.0 to 389.6) |
| Anti-HPV 18 | 130.3 (118.9 to 142.7) |
Serum antibody titers (Geometric mean titers) for HPV virus-like particles (VLPs) Types 6, 11, 16, and 18 were measured. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 87.6 (80.4 to 95.4) |
| Anti-HPV 11 | 67.3 (61.6 to 73.5) |
| Anti-HPV 16 | 283.2 (250.8 to 319.8) |
| Anti-HPV 18 | 113.6 (103.7 to 124.5) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 99.1 (97.4 to 99.8) |
| Anti-HPV 11 | 99.7 (98.3 to 100.0) |
| Anti-HPV 16 | 100.0 (98.9 to 100.0) |
| Anti-HPV 18 | 96.9 (94.3 to 98.5) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 88.8 (84.9 to 92.0) |
| Anti-HPV 11 | 95.3 (92.4 to 97.4) |
| Anti-HPV 16 | 99.7 (98.3 to 100.0) |
| Anti-HPV 18 | 87.7 (83.5 to 91.1) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 83.6 (79.1 to 87.5) |
| Anti-HPV 11 | 92.1 (88.6 to 94.8) |
| Anti-HPV 16 | 98.8 (96.9 to 99.7) |
| Anti-HPV 18 | 84.0 (79.4 to 87.9) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 68.5 (63.0 to 73.6) |
| Anti-HPV 11 | 85.2 (80.8 to 89.0) |
| Anti-HPV 16 | 91.9 (88.4 to 94.6) |
| Anti-HPV 18 | 64.6 (58.9 to 70.0) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using cLIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 61.9 (56.2 to 67.3) |
| Anti-HPV 11 | 74.9 (69.7 to 79.7) |
| Anti-HPV 16 | 87.1 (82.9 to 90.6) |
| Anti-HPV 18 | 58.3 (52.5 to 63.9) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 217.0 (198.1 to 237.6) |
| Anti-HPV 11 | 172.1 (158.3 to 187.1) |
| Anti-HPV 16 | 1025.8 (945.5 to 1113.0) |
| Anti-HPV 18 | 228.0 (204.4 to 254.4) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 85.5 (76.4 to 95.6) |
| Anti-HPV 11 | 68.6 (61.6 to 76.4) |
| Anti-HPV 16 | 394.9 (354.6 to 439.9) |
| Anti-HPV 18 | 76.9 (67.0 to 88.3) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA. Antibody titers were expressed as (mMU/mL).
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Anti-HPV 6 | 66.5 (59.6 to 74.1) |
| Anti-HPV 11 | 52.7 (47.2 to 58.8) |
| Anti-HPV 16 | 304.0 (272.2 to 339.5) |
| Anti-HPV 18 | 57.5 (50.0 to 66.1) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 63.4 (56.8 to 70.8) |
| Anti-HPV 11 | 51.1 (45.9 to 56.9) |
| Anti-HPV 16 | 289.6 (258.7 to 324.2) |
| Anti-HPV 18 | 55.3 (47.8 to 63.9) |
Serum antibody titers (Geometric mean titers) for HPV Types 6, 11, 16, and 18 were measured. Antibodies were measured using IgG LIA.
| mMU/mL | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 58.6 (52.5 to 65.4) |
| Anti-HPV 11 | 47.2 (42.4 to 52.5) |
| Anti-HPV 16 | 264.3 (235.8 to 296.3) |
| Anti-HPV 18 | 51.0 (44.0 to 59.1) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 100.0 (98.9 to 100.0) |
| Anti-HPV 11 | 100.0 (98.9 to 100.0) |
| Anti-HPV 16 | 100.0 (98.9 to 100.0) |
| Anti-HPV 18 | 100.0 (98.9 to 100.0) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 98.4 (96.4 to 99.5) |
| Anti-HPV 11 | 98.4 (96.4 to 99.5) |
| Anti-HPV 16 | 100.0 (98.9 to 100.0) |
| Anti-HPV 18 | 98.1 (95.9 to 99.3) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 98.1 (95.9 to 99.3) |
| Anti-HPV 11 | 99.4 (97.7 to 99.9) |
| Anti-HPV 16 | 100.0 (98.9 to 100.0) |
| Anti-HPV 18 | 96.2 (93.4 to 98.0) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 97.4 (95.0 to 98.9) |
| Anti-HPV 11 | 98.4 (96.3 to 99.5) |
| Anti-HPV 16 | 100.0 (98.9 to 100.0) |
| Anti-HPV 18 | 95.1 (92.0 to 97.2) |
The percentage of participants who are seropositive to each of HPV Types 6, 11, 16, and 18 were assessed. Antibodies were measured using IgG LIA.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Year |
|---|---|
| Anti-HPV 6 | 96.7 (94.1 to 98.4) |
| Anti-HPV 11 | 98.4 (96.2 to 99.5) |
| Anti-HPV 16 | 100.0 (98.8 to 100.0) |
| Anti-HPV 18 | 95.4 (92.3 to 97.4) |
Seroconversion is defined as changing serostatus from seronegative at Day 1 to seropositive at 1 month post dose 3. Antibodies were measured using a Competitive Luminex Immunoassay (cLIA). Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).
| Percentage of Participants | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Anti-HPV 6 | 100.0 | 100.0 |
| Anti-HPV 11 | 100.0 | 100.0 |
| Anti-HPV 16 | 100.0 | 100.0 |
| Anti-HPV 18 | 100.0 | 100.0 |
Antibodies to HPV Types 6, 11, 16, and 18 were measured using an IgG LIA. Antibody titers were expressed as milli Merck Units/milliliter (mMU/mL).
| mMU/mL | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Anti-HPV 6 | 902.7 (831.2 to 980.3) | 604.5 (554.7 to 658.8) |
| Anti-HPV 11 | 756.2 (695.7 to 821.9) | 518.7 (475.5 to 565.9) |
| Anti-HPV 16 | 4170.0 (3849.3 to 4517.4) | 2659.3 (2447.8 to 2889.0) |
| Anti-HPV 18 | 1012.8 (918.7 to 1116.5) | 612.0 (553.9 to 676.1) |
The percentage of participants who seroconverted to each of HPV Types 6, 11, 16, and 18 was assessed. Antibodies were measured using IgG LIA.
| Percentage of Participants | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Anti-HPV 6 | 100.0 | 100.0 |
| Anti-HPV 11 | 100.0 | 100.0 |
| Anti-HPV 16 | 100.0 | 100.0 |
| Anti-HPV 18 | 100.0 | 100.0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs included injection-site redness, swelling, induration, pain, and pruritus.
| Percentage of Participants | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Base Stage: Percentage of Participants Who Experienced a Solicited Injection-site Adverse Event (AE) | 36.6 | 40.7 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs included hypersensitivity, headache, fatigue, vomiting, nausea, diarrhea, myalgia, pyrexia, and cough.
| Percentage of Participants | Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Base Stage: Percentage of Participants Participants Who Experienced a Solicited Systemic AE | 39.9 | 42.0 |
An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
| Percentage of Participants | Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Base Stage: Percentage of Participants Who Experienced a Serious Adverse Event (SAE) | 1.6 | 2.87 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment
| Percentage of Participants | Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| Base Stage: Percentage of Participants Who Experienced an AE | 61.6 | 68.9 |
In the global studies, fever is defined as an oral temperature of ≥37.8°C or 100.0°F, which is equivalent to axillary temperature of ≥37.2°C, while the definition of fever is axillary temperature of ≥37.1°C in Chinese criteria. To be compliant to Chinese criteria, axillary temperatures of ≥37.1°C was considered as a fever in this study. Body temperature readings assessed orally were converted to the axillary equivalent. The percentage of participants with a maximum axillary or converted axillary temperature was summarized by temperature range.
| Percentage of Participants | Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years |
|---|---|---|
| < 37.2 °C (99.0 °F) | 87.2 | 84.9 |
| ≥37.2 °C (99.0 °F) and < 38.3 °C (100.9 °F) | 12.3 | 14.9 |
| ≥ 38.3 °C (100.9 °F) and < 39.3 °C (102.7 °F) | 0.3 | 0.3 |
| ≥ 39.3 °C (102.7 °F) and < 40.3 °C (104.5 °F) | 0.3 | 0.0 |
| ≥ 40.3 °C (104.5 °F) | 0.0 | 0.0 |
The percentage of participants with an SAE will be assessed. An SAE is an AE that results in death, is life threatening, requires hospitalization or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, according to medical or scientific judgment, may jeopardize the participant or requires medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
| Percentage of Participants | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|
| Extension Stage: Percentage of Participants Who Experienced an SAE | 2.2 |
Collected over Base Stage only: Up to approximately 7 months Extension Stage: Month 7 up to approximately 60 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Study: Chinese Girls Aged 9 to 19 Years | 0/383 (0%) | 6/383 (1.6%) | 216/383 (56.4%) |
| Base Study: Chinese Young Women Aged 20 to 26 Years | 0/383 (0%) | 11/383 (2.9%) | 238/383 (62.1%) |
| Extension Study: Chinese Girls Aged 9 to 19 Years | 0/365 (0%) | 8/365 (2.2%) | 0/365 (0%) |
| Event | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|---|---|
| Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions | 0/383 | 0/383 | 2/365 |
| Skin infectionInfections and infestations | 0/383 | 0/383 | 1/365 |
| Ligament sprainInjury, poisoning and procedural complications | 0/383 | 0/383 | 1/365 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/383 | 0/383 | 1/365 |
| Ulna fractureInjury, poisoning and procedural complications | 0/383 | 0/383 | 1/365 |
| EpendymomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/383 | 0/383 | 1/365 |
| Abortion threatenedPregnancy, puerperium and perinatal conditions | 0/383 | 0/383 | 1/365 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/383 | 0/383 | 1/365 |
| Foetal distress syndromePregnancy, puerperium and perinatal conditions | 0/383 | 0/383 | 1/365 |
| DermatitisSkin and subcutaneous tissue disorders | 0/383 | 0/383 | 1/365 |
| Event | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Extension Study: Chinese Girls Aged 9 to 19 Years |
|---|---|---|---|
| Injection site painGeneral disorders | 122/383 | 152/383 | 0/365 |
| PyrexiaGeneral disorders | 104/383 | 108/383 | 0/365 |
| FatigueGeneral disorders | 41/383 | 42/383 | 0/365 |
| HeadacheNervous system disorders | 32/383 | 42/383 | 0/365 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/383 | 41/383 | 0/365 |
| Injection site pruritusGeneral disorders | 32/383 | 16/383 | 0/365 |
| DiarrhoeaGastrointestinal disorders | 15/383 | 31/383 | 0/365 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 16/383 | 29/383 | 0/365 |
| Injection site swellingGeneral disorders | 22/383 | 11/383 | 0/365 |
Per protocol, baseline characteristics were analyzed in all participants randomized in the base study.
| Age, Continuous(years) | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Total |
|---|---|---|---|
| Mean | 14.3 ± 3.3 | 23.4 ± 1.8 | 18.8 ± 5.3 |
| Sex: Female, Male(Participants) | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Total |
|---|---|---|---|
| Female | 383 | 383 | 766 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 383 | 383 | 766 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Base Study: Chinese Girls Aged 9 to 19 Years | Base Study: Chinese Young Women Aged 20 to 26 Years | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 383 | 383 | 766 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Aug 2018 to primary completion in Oct 2023, 61 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18